News search

The research demonstrates the benefit of a new gene silencer for treating the disease

TROPOSplice proposes an evolution-inspired strategy to improve cardiac relaxation in patients with hypertrophic cardiomyopathy and heart failure with preserved ejection fraction.

Left ventricular hypertrabeculation, an anatomical feature of the heart traditionally linked to higher risk, does not worsen outcomes in patients with dilated cardiomyopathy

Hypertrophic cardiomyopathy is the most common inherited heart disease and the leading cause of sudden cardiac death in young people and athletes

The findings, published in Cardiovascular Research, show that the right ventricle has greater metabolic resilience than the left during cardiac arrest caused by ventricular fibrillation.

The biomarker MR-proADM improves risk prediction in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and is associated with greater disease severity, mortality, and heart failure events.

Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), together with cardiologists from Hospital Universitario Puerta de Hierro and the Spanish cardiovascular disease research network (CIBERCV), report that the new discovery makes it possible to identify high-risk patients early and refer them sooner to specialized heart failure units

A CNIC team has developed an innovative gene therapy strategy for arrhythmogenic right ventricular cardiomyopathy type 5 (ARVC5), a rare and deadly inherited condition that particularly affects young men